Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.
about
BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesisA phenotypic mouse model of basaloid breast tumorsPrepubertal physical activity up-regulates estrogen receptor beta, BRCA1 and p53 mRNA expression in the rat mammary glandGrowth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.Genetically engineered ERα-positive breast cancer mouse models.Estrogen signaling and the DNA damage response in hormone dependent breast cancers.Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesisAtbf1 regulates pubertal mammary gland development likely by inhibiting the pro-proliferative function of estrogen-ER signaling.Time-lapse imaging of primary preneoplastic mammary epithelial cells derived from genetically engineered mouse models of breast cancer.Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-αAltered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial contentComparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.Choosing a mouse model: experimental biology in context--the utility and limitations of mouse models of breast cancer.Mouse models of estrogen receptor-positive breast cancerA new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance.AKT regulates BRCA1 stability in response to hormone signaling.BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.Loss of BRCA1 leads to an increased sensitivity to Bisphenol A.Derailed estrogen signaling and breast cancer: an authentic couple.Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression.The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.BRCA1, hormone, and tissue-specific tumor suppressionTamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Primary cancer cell culture: mammary-optimized vs conditional reprogramming.Abnormal Mammary Adipose Tissue Environment of Brca1 Mutant Mice Show a Persistent Deposition of Highly Vascularized Multilocular Adipocytes.Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.Mouse models of BRCA1 and their application to breast cancer research.MicroRNA-206 is differentially expressed in Brca1-deficient mice and regulates epithelial and stromal cell compartments of the mouse mammary glandBRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients.Responsiveness of Brca1 and Trp53 Deficiency-Induced Mammary Preneoplasia to Selective Estrogen Modulators versus an Aromatase Inhibitor in Mus musculus.Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis.
P2860
Q26822737-A345E572-D0B2-48F7-8750-72AA86CA0258Q26853207-E1D36997-981C-44D5-BA9A-46A648B4C790Q28480588-984093C2-667A-48B2-A092-ECF7529313F4Q28573752-009C6C7D-EDAD-481E-A565-664AE3D5F418Q33569159-217459CE-84E6-4C1B-89C7-52DA73C1A1E4Q33576505-D1191131-81D7-45E9-BF37-3FE17F4BB2F5Q33578641-55EDBB80-039C-4212-B51D-2CBAAD274C38Q33646842-D7354A5B-FA66-4386-A224-FF3D7F4B9090Q33884587-3FBD9268-7E53-49C9-8F19-085BC6A03981Q34516351-6A425EFC-D1C6-452F-BB86-D210FA848DC7Q34593426-062B2E68-BEB5-4942-8F51-8B71BE4D0333Q34603057-3B2A06EA-725B-4F01-A5BD-71E959C7952CQ34712100-4BD02DBB-FDB2-4D4A-A865-5614708F0544Q34918110-B06B6BFF-236F-4804-B83D-D668924668B0Q35157919-77AF1EB0-F046-4DCE-B89F-C9E211D8B3BAQ35234634-3221589D-E559-427B-A92C-8561099E6660Q35685892-DD0850F1-18ED-442F-8AC4-3DF898BB6F7BQ35843483-45BDC07D-3BB2-4126-B1B1-390C2267B01CQ35994422-1B801453-C502-436A-A468-546A49C0089CQ36406519-806D9AB3-2D9E-4837-BDDC-EC77966F5A04Q36422318-6C92B782-6C12-4801-8E04-C84A840E4464Q36589361-E7C87A5E-B890-4E48-AD20-BD492A0168D7Q36738875-59C0CD73-5ADC-4999-8532-B35233F2DA98Q36888347-FD008E4E-5CEB-492E-8BF5-AB2BA6F73CA0Q36982090-B6C95B4B-2D7C-49FF-A8B7-32F661656224Q37020551-8F0FE274-577F-4F63-9399-A45903D3E171Q37122297-61461F6A-6E1C-4CF1-971D-CB66AAC2A9E6Q37130539-2B13298F-3191-4FFC-BEAB-75BF1DE5BD95Q37364047-47D6DA13-D693-4D48-80B6-0216EAB3834AQ37564411-4E3667EA-0A39-4976-B2DD-6E712510D38CQ37692442-5E7B7949-CBAE-42B4-8EF8-42BD4B47E98EQ37955050-3402E2CF-E9E1-481B-9C19-EE29D700EA89Q38055069-8AD39661-E716-454C-AD7D-1C5324F1CD7DQ40747141-15665834-CBE9-401C-A9C7-2BA75A1F439DQ42777355-C1436D46-40FC-43AB-A349-5D0A05CE364EQ43624639-A847595B-7772-4D62-8326-48DF080E2CF7Q43943310-99355CC2-22BC-45F3-ACF0-964350F532E8Q51102156-BF473A80-2CD6-488D-99D0-281D170E2035Q53287132-BC2EC872-DBB1-433E-8154-8222562EC9D3
P2860
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Activation of estrogen signali ...... mmary preneoplasia and cancer.
@ast
Activation of estrogen signali ...... mmary preneoplasia and cancer.
@en
Activation of estrogen signali ...... mmary preneoplasia and cancer.
@nl
type
label
Activation of estrogen signali ...... mmary preneoplasia and cancer.
@ast
Activation of estrogen signali ...... mmary preneoplasia and cancer.
@en
Activation of estrogen signali ...... mmary preneoplasia and cancer.
@nl
prefLabel
Activation of estrogen signali ...... mmary preneoplasia and cancer.
@ast
Activation of estrogen signali ...... mmary preneoplasia and cancer.
@en
Activation of estrogen signali ...... mmary preneoplasia and cancer.
@nl
P2093
P2860
P356
P1433
P1476
Activation of estrogen signali ...... mmary preneoplasia and cancer.
@en
P2093
E D Halama
S Assefnia
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210674
P407
P577
2007-07-23T00:00:00Z
P5875
P6179
1043452769